Literature DB >> 17024496

Differences in expression of junctional adhesion molecule-A and beta-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology.

Maureen Padden1, Susie Leech, Beverly Craig, John Kirk, Brenda Brankin, Stephen McQuaid.   

Abstract

Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use of antibodies to the independent TJ-specific proteins and junctional adhesion molecule A & B (JAM-A, JAM-B). We have also assessed the expression in MS of beta-catenin, a protein specific to the TJ-associated adherens junction. Immunocytochemistry and semiquantitative confocal microscopy for JAM-A and beta-catenin was performed on snap-frozen sections from MS cases (n=11) and controls (n=6). Data on 1,443 blood vessels was acquired from active lesions (n=13), inactive lesions (n=13), NAWM (n=20) and control white matter (n=13). In MS abnormal JAM-A expression was found in active (46%) and inactive lesions (21%), comparable to previous data using ZO-1. However, a lower level of TJ abnormality was found in MS NAWM using JAM-A (3%) compared to ZO-1 (13%). JAM-B was strongly expressed on a small number of large blood vessels in control and MS tissues but at too low a level for quantitative analysis. By comparison with the high levels of abnormality observed with the TJ proteins, the adherens junction protein beta-catenin was normally expressed in all MS and control tissue categories. These results confirm, by use of the independent marker JAM-A, that TJ abnormalities are most frequent in active white matter lesions. Altered expression of JAM-A, in addition to affecting junctional tightness may also both reflect and affect leukocyte trafficking, with implications for immune status within the diseased CNS. Conversely, the adherens junction component of the TJ, as indicated by beta-catenin expression is normally expressed in all MS and control tissue categories.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024496     DOI: 10.1007/s00401-006-0145-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  24 in total

1.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

2.  Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.

Authors:  Friederike Pfeiffer; Julia Schäfer; Ruth Lyck; Victoria Makrides; Sarah Brunner; Nicole Schaeren-Wiemers; Urban Deutsch; Britta Engelhardt
Journal:  Acta Neuropathol       Date:  2011-10-09       Impact factor: 17.088

3.  Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis.

Authors:  Justin E Lengfeld; Sarah E Lutz; Julian R Smith; Claudiu Diaconu; Cameron Scott; Sigal B Kofman; Claire Choi; Craig M Walsh; Cedric S Raine; Ilir Agalliu; Dritan Agalliu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

4.  Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective.

Authors:  Hideaki Nishihara; Britta Engelhardt
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.

Authors:  Alexandre Vallée; Jean-Noël Vallée; Rémy Guillevin; Yves Lecarpentier
Journal:  Cell Mol Neurobiol       Date:  2017-09-13       Impact factor: 5.046

6.  Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown.

Authors:  Axel Haarmann; Annika Deiss; Jürgen Prochaska; Christian Foerch; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Guido Stoll; Peter Rieckmann; Mathias Buttmann
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

Review 7.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

8.  Changes of AXIN-1 and beta-catenin in neuroepithelial brain tumors.

Authors:  Tamara Nikuseva Martić; Nives Pećina-Slaus; Vesna Kusec; Tomislav Kokotović; Hana Musinović; Davor Tomas; Martina Zeljko
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

Review 9.  Methods used for the measurement of blood-brain barrier integrity.

Authors:  Huixin Sun; Huiling Hu; Chuanjie Liu; Nannan Sun; Chaohui Duan
Journal:  Metab Brain Dis       Date:  2021-02-26       Impact factor: 3.584

10.  Keratinocytes as depository of ammonium-inducible glutamine synthetase: age- and anatomy-dependent distribution in human and rat skin.

Authors:  Lusine Danielyan; Sebastian Zellmer; Stefan Sickinger; Genrich V Tolstonog; Jürgen Salvetter; Ali Lourhmati; Dieter D Reissig; Cristoph H Gleiter; Rolf Gebhardt; Gayane Hrachia Buniatian
Journal:  PLoS One       Date:  2009-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.